Clearmind Medicine Closes US$2.25 Million Public Offering Post published:September 18, 2023 Post category:Press Release
Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression Post published:September 18, 2023 Post category:Press Release
Optimi Health Celebrates Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial Post published:September 14, 2023 Post category:Press Release
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering Post published:September 14, 2023 Post category:Press Release
BetterLife Pharma to Host Investors Update Call on September 18, 2023 Post published:September 14, 2023 Post category:Press Release
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference Post published:September 14, 2023 Post category:Press Release
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD Post published:September 12, 2023 Post category:Press Release
BetterLife Obtains Favourable Animal Safety Data for Repeated Oral Dosing of BETR-001 Post published:September 12, 2023 Post category:Press Release
Optimi Health Granted Amendment to Dealer's Licence by Health Canada to Supply Special Access Program Post published:September 7, 2023 Post category:Press Release
atai Life Sciences to Participate in Upcoming September Investor Conferences Post published:September 6, 2023 Post category:Press Release